Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:CABA NASDAQ:CUE NASDAQ:ENTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.99+2.0%$3.03$1.20▼$4.11$227.19M3.071.79 million shs757,408 shsCABACabaletta Bio$2.41+3.9%$1.81$0.99▼$5.46$220.42M3.011.64 million shs3.99 million shsCUECue Biopharma$0.86+14.0%$0.77$0.54▼$1.99$65.94M1.55244,608 shs597,139 shsENTAEnanta Pharmaceuticals$11.30+2.0%$8.49$4.09▼$15.34$241.59M0.89402,754 shs584,397 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-0.26%+3.17%+32.99%+48.11%+6.83%CABACabaletta Bio-4.92%-0.85%+36.47%+35.67%-42.14%CUECue Biopharma+3.42%+4.69%-3.54%-3.94%-45.68%ENTAEnanta Pharmaceuticals-2.38%-7.44%+25.20%+55.40%-4.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.99+2.0%$3.03$1.20▼$4.11$227.19M3.071.79 million shs757,408 shsCABACabaletta Bio$2.41+3.9%$1.81$0.99▼$5.46$220.42M3.011.64 million shs3.99 million shsCUECue Biopharma$0.86+14.0%$0.77$0.54▼$1.99$65.94M1.55244,608 shs597,139 shsENTAEnanta Pharmaceuticals$11.30+2.0%$8.49$4.09▼$15.34$241.59M0.89402,754 shs584,397 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-0.26%+3.17%+32.99%+48.11%+6.83%CABACabaletta Bio-4.92%-0.85%+36.47%+35.67%-42.14%CUECue Biopharma+3.42%+4.69%-3.54%-3.94%-45.68%ENTAEnanta Pharmaceuticals-2.38%-7.44%+25.20%+55.40%-4.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.86Moderate Buy$11.00175.69% UpsideCABACabaletta Bio 2.80Moderate Buy$14.50501.66% UpsideCUECue Biopharma 1.00SellN/AN/AENTAEnanta Pharmaceuticals 2.71Moderate Buy$20.8384.37% UpsideCurrent Analyst Ratings BreakdownLatest CUE, CABA, BDTX, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BDTXBlack Diamond TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025CABACabaletta BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ENTAEnanta PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/1/2025ENTAEnanta PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$14.00 ➝ $20.009/30/2025ENTAEnanta PharmaceuticalsWestpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $28.009/27/2025BDTXBlack Diamond TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025CABACabaletta BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CUECue BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ENTAEnanta PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/15/2025ENTAEnanta PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $12.009/5/2025CABACabaletta BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$15.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$1.47 per shareN/ACABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/ACUECue Biopharma$9.29M7.10N/AN/A$0.28 per share3.06ENTAEnanta Pharmaceuticals$67.64M3.57N/AN/A$6.08 per share1.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.2317.35N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)CABACabaletta Bio-$115.86M-$2.71N/AN/AN/AN/A-92.11%-74.08%11/13/2025 (Estimated)CUECue Biopharma-$40.67M-$0.56N/AN/AN/A-469.35%-230.13%-111.16%11/13/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.32N/AN/AN/A-141.98%-89.02%-27.28%12/1/2025 (Estimated)Latest CUE, CABA, BDTX, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025BDTXBlack Diamond Therapeutics-$0.23N/AN/AN/AN/AN/A8/12/2025Q2 2025CUECue Biopharma-$0.13-$0.09+$0.04-$0.09$2.00 million$2.95 million8/11/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.25-$0.85+$0.40-$0.85$16.21 million$18.31 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/A8/7/2025Q2 2025CABACabaletta Bio-$0.71-$0.73-$0.02-$0.73$4.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.738.73CABACabaletta BioN/A4.784.78CUECue Biopharma0.011.601.60ENTAEnanta PharmaceuticalsN/A5.005.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%CABACabaletta BioN/ACUECue Biopharma35.04%ENTAEnanta Pharmaceuticals94.99%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%CABACabaletta Bio11.25%CUECue Biopharma12.26%ENTAEnanta Pharmaceuticals13.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableCABACabaletta Bio5091.46 million81.18 millionOptionableCUECue Biopharma6076.85 million67.43 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableCUE, CABA, BDTX, and ENTA HeadlinesRecent News About These CompaniesLeerink Partnrs Has Strong Estimate for ENTA FY2027 EarningsOctober 4, 2025 | americanbankingnews.comEnanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesOctober 3, 2025 | tmcnet.comEnanta Pharmaceuticals (NASDAQ:ENTA) Raised to Buy at Jefferies Financial GroupOctober 3, 2025 | americanbankingnews.comEnanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesOctober 2, 2025 | finance.yahoo.comFY2027 Earnings Estimate for ENTA Issued By Leerink PartnrsOctober 2, 2025 | marketbeat.comWestpark Capital Issues Positive Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock PriceOctober 2, 2025 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Increased to Buy at Jefferies Financial GroupOctober 1, 2025 | marketbeat.comCal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionOctober 1, 2025 | benzinga.comEnanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockSeptember 30, 2025 | businesswire.comEnanta up 92% as zelicapavir’s RSV journey goes onSeptember 30, 2025 | thepharmaletter.comTEnanta's RSV treatment helps speed up recovery in study, shares surgeSeptember 30, 2025 | msn.comEnanta Pharmaceuticals stock falls after announcing $50 million offeringSeptember 30, 2025 | za.investing.comWestPark Capital Maintains Enanta Pharmaceuticals (ENTA) Buy RecommendationSeptember 30, 2025 | msn.comEnanta Pharmaceuticals Announces Proposed Public Offering of Common StockSeptember 30, 2025 | businesswire.comEnanta Pharmaceuticals (NASDAQ:ENTA) Price Target Raised to $28.00September 30, 2025 | marketbeat.comEnanta stock tumbles after RSV drug misses primary endpointSeptember 29, 2025 | za.investing.comEnanta's RSV treatment misses main goal in mid-stage studySeptember 29, 2025 | msn.comEnanta shares rise despite RSV trial failing to meet main goalSeptember 29, 2025 | msn.comEnanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk AdultsSeptember 29, 2025 | finance.yahoo.comEnanta Pharmaceuticals Stock Rises 58% – Here’s An Important UpdateSeptember 29, 2025 | msn.comEnanta Pharmaceuticals, Inc. - Special CallSeptember 29, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUE, CABA, BDTX, and ENTA Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$3.99 +0.08 (+2.05%) Closing price 04:00 PM EasternExtended Trading$3.99 0.00 (0.00%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Cabaletta Bio NASDAQ:CABA$2.41 +0.09 (+3.88%) Closing price 04:00 PM EasternExtended Trading$2.43 +0.02 (+0.83%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Cue Biopharma NASDAQ:CUE$0.86 +0.11 (+14.04%) Closing price 04:00 PM EasternExtended Trading$0.83 -0.03 (-3.26%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$11.30 +0.22 (+1.99%) Closing price 04:00 PM EasternExtended Trading$11.30 -0.01 (-0.04%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Will Firefly’s $855M SciTec Acquisition Ignite a Stock Re-Rating? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
